advertisement
Abstract #47869 Published in IGR 13-4
Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
Syed MF; Loucks EKRClinical Ophthalmology 2011; 5: 1291-1296
Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga(registered trademark) for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the "washout effect" from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives. (copyright) 2011 Syed and Loucks.
M. F. Syed. Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, 700 University Boulevard, Galveston, TX 77555, United States. Email: mfsyed@utmb.edu
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)